FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Medical Devices

Disclose Locked Hearing Aids: Members of Congress

A bipartisan group of 11 Senate and House members asks FDA to require hearing aid labeling to disclose if the device uses proprietary software that af...

latest-news-card-1
Human Drugs

ICH M12 Drug Interaction Guideline Out

The International Council on Harmonization publishes the M12 final guideline on drug interactions and an accompanying question-and-answer document.

latest-news-card-1
Federal Register

Info Collection on Device De Novo Requests

Federal Register notice: FDA seeks comments on an OMB information collection extension entitled De Novo Classification Process (Evaluation of Automati...

latest-news-card-1
Federal Register

Invivyds Pemgarda Gets EUA for Covid

Federal Register notice: FDA announces the issuance of an emergency use authorization for Invivyds Pemgarda (pemivibart) for use as Covid-19 pre-expos...

latest-news-card-1
Medical Devices

Ostar Beauty Selling Unapproved Medical Devices: FDA

FDA warns Chinas Ostar Beauty Sci-Tech about illegally marketing unapproved medical devices.

latest-news-card-1
Human Drugs

Multiple Violations in Lengthy Biomic Inspection

FDA warns Charlottesville, VA-based ION Intelligence of Nature about multiple violations in its production of drugs and dietary supplements.

latest-news-card-1
Medical Devices

Spinearts Scarlet Anterior Cervical Cage Cleared

FDA clears a Spineart 510(k) for its Scarlet AC-Ti secured anterior cervical cage.

latest-news-card-1
Human Drugs

Teva Spurns FDAs Beta-Lactam Drug Recommendation

Teva says FDA should drop its recommendation for the use of dedicated manufacturing facilities for ezetimibe to prevent cross-contamination.

Human Drugs

ICH Pharmacoepidemiological Study Guidance Out

FDA publishes for comment the International Council for Harmonization M14 guidance on general principles for planning, designing, and analyzing pharma...

latest-news-card-1
Biologics

Sanofi Sarclisa sBLA Accepted for Priority Review

FDA accepts for priority review a Sanofi supplemental BLA for Sarclisa (isatuximab) in combination with standard of care for treating patients with tr...